Jeff P. <a>Sharman</a>, MD, discusses the safety profile of acalabrutinib that was demonstrated in <a href="https://www.targetedonc.com/conference/ash-2019/patients-with-cll-treated-on-the-elevatetn-trial-experience-improved-pfs-with-acalabrutinib"><strong>the phase III ELEVATE-TN trial</strong></a>. The trial evaluated acalabrutinib as a single agent or in combination with obinutuzumab versus obinutuzumab plus chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia.
